Patrizia Zappasodi

Dr. Patrizia Zappasodi


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2020 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
ACANNA CANDONI
ANNA CANDONI
DLDavide Lazzarotto
Davide Lazzarotto
FFFelicetto Ferrara
Felicetto Ferrara
ACAntonio Curti
Antonio Curti
FLFederico Lussana
Federico Lussana
RFRoberto Foà
Roberto Foà

10 October 2025 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
UPUwe Platzbecker
Uwe Platzbecker
LALionel Adès
Lionel Adès
PMPau Montesinos
Pau Montesinos
EAEmanuele Ammatuna
Emanuele Ammatuna
PFPierre Fenaux
Pierre Fenaux
SZSven Zukunft
Sven Zukunft
PURPOSE: The phase III APOLLO trial prospectively compared the efficacy of arsenic trioxide (ATO) in combination with all-trans retinoic acid (ATRA) regimen (ATRA and ATO [ATRA-ATO]) plus low-dose idarubicin versus standard ATRA plus anthracycline-based chemotherapy (ATRA-CHT) regimen (ie, ATRA and idarubicin regimen) in patients with high-risk acute promyelocytic leukemia (APL; EudraCT 2015-01151-68; ClinicalTrials.gov identifier: NCT02688140 ). METHODS: Adult patients with newly diagnosed high-risk APL in the ATRA-ATO arm received ATO 0.15 mg/kg once daily and ATRA 45 mg/m 2 twice daily until complete remission (CR), with two doses of idarubicin 12 mg/m 2 on days 1 and 3, followed by consolidation therapy (four ATRA-ATO cycles). Patients in the ATRA-CHT arm received induction with ATRA 45 mg/m 2 twice daily and idarubicin 12 mg/m 2 once daily on days 1, 3, 5, and 7, followed by three cycles of chemotherapy-based consolidation and 2 years of maintenance therapy. The primary study end point was event-free survival (EFS) at 2 years. RESULTS: As of July 2022, 133 eligible patients had received either ATRA-ATO (n = 68) or ATRA-CHT (n = 65). The study was discontinued prematurely because of slow accrual during the COVID-19 pandemic. After a median follow-up of 37 months (range, 1.7-88.6 months), 2-year EFS was 88% in the ATRA-ATO arm and 71% in the ATRA-CHT arm (HR, 0.4 [95% CI, 0.17 to 0.92]; log-rank test P = .02). At a median of 7.8 and 12.1 months from achievement of CR, molecular relapse occurred in one (1.5%) ATRA-ATO patient versus eight (12.3%) ATRA-CHT patients ( P = .014). Overall, 32% and 68% of patients receiving ATRA-ATO and ATRA-CHT, respectively, reported serious treatment-emergent adverse events ( P < .01). CONCLUSION: The results of the APOLLO trial support the use of ATO and ATRA for the treatment of newly diagnosed patients with high-risk APL.

8 June 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SGSimona De Gregori
Simona De Gregori
EGEleonora Gelli
Eleonora Gelli
MCMara Capone
Mara Capone
GGGiulia Gambini
Giulia Gambini
ERElisa Roncoroni
Elisa Roncoroni
PZPatrizia Zappasodi
Patrizia Zappasodi
The Food and Drug Administration currently approves the combination of hypomethylating agents (HMA), azacytidine or decitabine with venetoclax (VEN) for acute myeloid leukemia (AML) patients aged more than 75 years and for patients unsuitable for intensive chemotherapy. The risk of fungal infection in the early phase of treatment is not negligible; therefore, posaconazole (PCZ) is commonly administered as primary prophylaxis. A drug–drug interaction between VEN and PCZ is well known, but the trend of serum levels of venetoclax when both drugs are overlapped is not clear. In total, 165 plasma samples from 11 elderly AML patients receiving combined treatment with HMA, VEN and PCZ were analyzed by a validated analytical method (high-pressure liquid chromatography–tandem mass spectrometry). Venetoclax trough plasma concentrations were detected during the 3 days of ramp-up as well as on day 7 and day 12 of treatment when the exposure as the area under the plasma concentration–time curve and the accumulation ratio were also calculated. The results were compared with the expected data for 400 mg/dose VEN administered alone—the confirmed high inter-individual variability in pharmacokinetics suggests the need for therapeutic drug monitoring.

5 January 2006 in International Journal of Dermatology
Verified
Journal Article
Open access
PDF file
PZPatrizia Zappasodi
Patrizia Zappasodi
CFCorrado Del Forno
Corrado Del Forno
ACAlessandro Corso
Alessandro Corso
MLMario Lazzarino
Mario Lazzarino

1 July 2003 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
ACA. Corso
A. Corso
PZPatrizia Zappasodi
Patrizia Zappasodi
CPC. Pascutto
C. Pascutto
TBT. Bosoni
T. Bosoni
SMS. Mangiacavalli
S. Mangiacavalli
MLM. Lazzarino
M. Lazzarino

19 September 2023 in Cancers
Verified
Journal Article
Open access
PDF file
NFNicola Stefano Fracchiolla
Nicola Stefano Fracchiolla
MSMariarita Sciumè
Mariarita Sciumè
CPCristina Papayannidis
Cristina Papayannidis
AVAntonella Vitale
Antonella Vitale
SCSabina Chiaretti
Sabina Chiaretti
Antonio CurtiAntonio Curti
Antonio Curti
Background: Blinatumomab (Blina) and inotuzumab ozogamicin (InO) has improved the outcome of relapsed/refractory B-lymphoblastic leukemia (R/R B-ALL). However, little is known about the outcome after recurrence and re-treatment with immunotherapy. Methods: We describe 71 R/R B-ALL patients treated for different relapses with Blina and InO. Blina was the first treatment in 57 patients and InO in 14. Twenty-seven patients had a previous allogeneic hematopoietic stem cell transplantation (allo-HSCT). Results: In the Blina/InO group, after Blina, 36 patients (63%) achieved a complete remission (CR), with 42% of negative minimal residual disease (MRD−); after InO, a CR was achieved in 47 patients (82%, 34 MRD−). In the InO/Blina group, after InO, 13 cases (93%) reached a CR (6 MRD−); after Blina, a CR was re-achieved in 6 cases (43%, 3 MRD−). Twenty-six patients proceeded to allo-HSCT. In the Blina/InO group, the median overall survival (OS) was 19 months; the disease-free survival (DFS) after Blina was 7.4 months (11.6 vs. 2.7 months in MRD− vs. MRD+, p = 0.03) and after InO, 5.4 months. In the InO/Blina group, the median OS was 9.4 months; the median DFS after InO was 5.1 months and 1.5 months after Blina (8.7 vs. 2.5 months in MRD− vs. MRD+, p = 0.02). With a median follow-up of 16.5 months from the start of immunotherapy, 24 patients (34%) are alive and 16 (22%) are alive in CR. Conclusion: In our series of R/R B-ALL, Blina and InO treatment demonstrate efficacy for subsequent relapses in terms of MRD response, OS and DFS, and as a bridge to allo-HSCT.